- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01943695
Supervised Aerobic Training During or After Chemotherapy for Operable Breast Cancer
Optimal Timing Trial: Randomized Trial of Supervised Aerobic Training During or After Chemotherapy for Operable Breast Cancer
The purpose of this study is to compare the effects of aerobic exercise training during and after chemotherapy for women who have recently been diagnosed with early-stage breast cancer.
The participant will be instructed to self-report the session information to ExOnc staff at or before their next scheduled visit. If the participant's next scheduled visit is greater than 72 hours following an unsupervised session, ExOnc staff may reach out to the participant to retrieve the session information. Unsupervised session details will be source documented by ExOnc staff.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged 21-80 years
- Female
- MSK histologically confirmed early-stage operable breast cancer
- Scheduled to receive chemotherapy in the neoadjuvant or adjuvant setting
- ECOG status of 0 or 1
- Performing less than 150 minutes of structured moderate-intensity or strenuous intensity exercise per week
If a female of child-bearing potential, must not be pregnant or planning to become pregnant during the study.
a. Women < 50 years old must have a negative pregnancy test (urine HCG or serum βHCG) within 2 weeks of beginning chemotherapy.
- Able to complete an acceptable baseline cardiopulmonary exercise test (CPET), in the absence of high risk ECG findings or other inappropriate response to exercise as determined by the investigator.
Able to achieve an acceptable peak baseline CPET, as defined by any of the following criteria:
- Achieving a plateau in oxygen consumption, concurrent with an increase in power output;
- A respiratory exchange ratio ≥ 1.10;
- Attainment of maximal predicted heart rate (HRmax) (i.e., within 10 bpm of age-predicted HRmax [HRmax = 220-Age[years]);
- Volitional exhaustion, as measured by a rating of perceived exertion (RPE) ≥ 18 on the BORG scale.
- Willingness to be randomized to one of the study arms
Exclusion Criteria:
- Presence of any other concurrent, actively treated malignancy
- History of any other malignancy treated within the past 3 years (other than non-melanoma skin cancer)
- Presence of metastatic disease
- Any of the following contraindications to cardiopulmonary exercise testing:
- Acute myocardial infarction within 3-5 days of any planned study procedures)
- Unstable angina
- Uncontrolled arrhythmia causing symptoms or hemodynamic compromise;
- Recurrent syncope
- Active endocarditis
- Acute myocarditis or pericarditis
- Symptomatic severe aortic stenosis
- Uncontrolled heart failure
- Acute pulmonary embolus or pulmonary infarction within 3 months of any planned study procedures;
- Thrombosis of lower extremities
- Suspected dissecting aneurysm
- Uncontrolled asthma
- Pulmonary edema
- Respiratory failure
- Acute non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (i.e., infection, renal failure, thyrotoxicosis) or
- Room air desaturation at rest ≤ 85%
- Mental impairment leading to inability to cooperate.
- Any other condition or intercurrent illness that, in the opinion of the investigator, makes the participant a poor candidate for the trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Aerobic Training During Chemotherapy
The ultimate goal is for participants to complete approximately 3 exercise sessions week of non-linear aerobic training an intensity of at 55% to 100% of the individually determined exercise capacity VO2peak), concurrent with chemotherapy.
VO2peak will be determined by the CPET performed at baseline.
The weekly exercise will be achieved via 3 individual aerobic training sessions ranging from approximately 20-45 min/session.
All sessions are required to be supervised unless otherwise specified by EP discretion.
|
Other Names:
|
Experimental: Aerobic Training After Chemotherapy
The ultimate goal is for participants to complete approximately 3 exercise sessions week of non-linear aerobic training at an intensity 55% to 100% of the individually determined exercise capacity (VO2peak), after the completion of chemotherapy.
VO2peak will be determined by the CPET performed at midpoint, or pre-surgery for neoadjuvant patients.
For patients receiving adjuvant therapy, (except those who have additional surgery after chemotherapy), the aerobic training intervention must begin within 2 weeks of the patient's midpoint CPET.
For patients receiving neoadjuvant or adjuvant therapy and have additional surgery after chemotherapy, the aerobic training intervention will begin within approximately 6 weeks of surgery, per the discretion of the treating physician.
The weekly exercise will be achieved via 3 individual aerobic training sessions ranging from approximately 20-45 min/session.
All sessions are required to be supervised unless otherwise specified by EP discretion.
|
Other Names:
|
Experimental: Continuous Aerobic Training
The ultimate goal is for participants to complete 3 exercise sessions week of non-linear aerobic training at 55% to 100% of the individually determined exercise capacity (VO2peak), during and after chemotherapy.
For patients receiving adjuvant therapy (except those who have additional surgery after chemotherapy), VO2peak will be determined by the CPETs performed at baseline and midpoint.
For patients receiving neoadjuvant or adjuvant therapy and have additional surgery after chemotherapy, VO2peak will be determined by the CPETs or at baseline, pre- surgery, and post-surgery.
The weekly exercise will be achieved via 3 individual aerobic training sessions ranging from approximately 20-45 min/session.
All sessions are required to be supervised unless otherwise specified by EP discretion.
|
Other Names:
|
Experimental: General Physical Activity Group
Patients will receive a home-based, general physical activity program.
Specifically, all patients assigned to general physical activity will receive an initial, consultation with a staff exercise physiologist outlining a structured home-based aerobic walking program with a goal up to 150 minutes per week outside of their normal daily activity.
Patients can be provided with a fitness tracker (e.g.
FitBit) to evaluate exercise duration and intensity.
Patients may also be provided with an exercise log to record type, duration, and average heart rate during sessions.
The exercise log is provided as a guidance tool and may be, although is not required to be, returned to study staff.
Staff exercise physiologists will contact patients to check progress, and answer questions.
|
Subjects will be given material regarding cancer and it's impact.
Patients that elect supervised home based training platform or plan to complete unsupervised training sessions will receive a study kit which includes a heart rate monitor, blood pressure cuff, treadmill and tablet to complete aerobic training requirements.
The study kit will be given to the patient upon completion of their baseline testing.
The treadmill will be shipped to the patient's home and coordinated by the Ex Onc group.
The treadmills are MSK owned equipment that will be deployed to the patient's homes via the vendor TechnoGym.
A member of Ex Onc will provide an orientation session for the patient to set up all study kit items.
If there is a delay in the patient receiving the treadmill , or any other unforeseen circumstance, patients may be assigned a temporary unsupervised training program until the treadmill is delivered.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in VO2 peak (functional capacity)
Time Frame: during chemotherapy 3-6 months depending on treatment recommendations
|
To determine the optimal timing of aerobic activity, relative to an attention-control group, on exercise capacity in a breast cancer setting.
This will be evaluated using an electronic motorized treadmill test with 12-lead ECG monitoring (Mac® 5000, GE Healthcare) performed by certified exercise physiologists.
|
during chemotherapy 3-6 months depending on treatment recommendations
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of Life measured by questionnaire during and after Chemotherapy
Time Frame: at baseline, mid-point (12 weeks approximately) , and follow-up (24 weeks approximately) testing
|
Determine the effects on patient-reported outcomes.
Time frame can vary based on individual length of chemotherapy.
|
at baseline, mid-point (12 weeks approximately) , and follow-up (24 weeks approximately) testing
|
Sleeping patterns as measured by questionnaire during and after Chemotherapy
Time Frame: at baseline, mid-point (12 weeks approximately) , and follow-up (24 weeks approximately) testing
|
Determine the effects on patient-reported outcomes.
Time frame can vary based on individual length of chemotherapy.
|
at baseline, mid-point (12 weeks approximately) , and follow-up (24 weeks approximately) testing
|
Depression scale during and after Chemotherapy
Time Frame: at baseline, mid-point (12 weeks approximately) , and follow-up (24 weeks approximately) testing
|
Determine the effects on patient-reported outcomes.
Time frame can vary based on individual length of chemotherapy.
|
at baseline, mid-point (12 weeks approximately) , and follow-up (24 weeks approximately) testing
|
Physical activity recall during and after Chemotherapy
Time Frame: at baseline, mid-point (12 weeks approximately) , and follow-up (24 weeks approximately) testing
|
Determine the effects on patient-reported outcomes.
Time frame can vary based on individual length of chemotherapy.
|
at baseline, mid-point (12 weeks approximately) , and follow-up (24 weeks approximately) testing
|
Skeletal Muscle Function
Time Frame: at baseline, mid-point (12 weeks approximately) , and follow-up (24 weeks approximately) testing
|
To examine the physiological mediators of the exercise training - exercise capacity relationship (e.g., skeletal muscle function as assessed by a muscle biopsy)performed.
|
at baseline, mid-point (12 weeks approximately) , and follow-up (24 weeks approximately) testing
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jessica Scott, PhD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15-178
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Aerobic Training
-
Riphah International UniversityRecruiting
-
University of BarcelonaCompleted
-
General Hospital Murska SobotaUniversity of Primorska; University of LjubljanaUnknownCoronary Artery Disease | Heart Failure With Reduced Ejection FractionSlovenia
-
Hadassah Medical OrganizationCompletedThe Influence of Different Training Regimens on Electrical Stability Following Myocardial InfarctionIschemic Heart Disease | Congestive Heart FailureIsrael
-
Riphah International UniversityCompletedMyocardial InfarctionPakistan
-
Riphah International UniversityCompleted
-
Clare MaguireRehab Basel; Bildungszetrum Gesundheit Basel-StadtCompleted
-
University of GiessenHannover Medical SchoolUnknownType 2 DiabetesGermany
-
Cardenal Herrera UniversityNot yet recruiting
-
UNC Lineberger Comprehensive Cancer CenterCompletedStem Cell Transplantation, HematopoieticUnited States